There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for your convenience. Catch up on what you might have missed below!

My fellow Altascientists and I recently attended the 2024 annual Boston Society G

The Challenges With Outsourcing Drug Development

In a Biopharma Dive survey, 45% of the over 143 biopharmaceutical executives surveyed cited the inability to adhere to tight deadlines as a common challenge in preclinical and Phase I clinical development.

Altasciences is leading the conversation on change in the drug development industry as part of a new documentary series for the 2024 Global Health Summit, hosted alongside the WHO’s 77th World Health Assembly in Geneva in May. The mini documentary explores transformation in the slow-to-change drug development industry.

Monitoring both cytokines and complement factors in drug development has become increasingly important, as the movement toward personalized treatments for cancers and genetic diseases has spurred research and development into biologics, vaccines, and small molecules that can have unintended consequences due to their immunomodulatory effects. 

Recent advances in gene therapy have allowed for diseases to be approached differently. Gene therapy was first discovered in the 1960s, but only gained commercial interest in the 1980s. It wasn’t until 1990 that the first successful gene therapy treatment on a patient transpired.